Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Core Insights - Altamira Therapeutics has successfully launched Bentrio in Norway and has extended its exclusive distribution agreement with Pharma Nordic AS to include Sweden and Denmark, aiming to introduce the product in these markets next year [1][2] Company Overview - Altamira Therapeutics is focused on developing peptide-based nanoparticle technologies for RNA delivery, with two flagship siRNA programs in preclinical development targeting KRAS-driven cancer and rheumatoid arthritis [4] - The company holds a 49% stake in Altamira Medica AG, which commercializes Bentrio, an OTC nasal spray for allergic rhinitis [4] Product Details - Bentrio is a drug-free nasal spray designed to protect against airborne allergens and viruses, forming a protective gel layer in the nasal mucosa [3] - Clinical trials, including the NASAR study with 100 participants, demonstrated Bentrio's efficacy in reducing nasal symptoms and improving quality of life compared to saline [3] Market Expansion - The positive reception of Bentrio in Norway has prompted plans for its introduction in Sweden and Denmark, where there is a shared interest in innovative healthcare products [2][3]